HC Wainwright Issues Pessimistic Forecast for BioNTech (NASDAQ:BNTX) Stock Price
BioNTech (NASDAQ:BNTX – Get Free Report) had its target price dropped by analysts at HC Wainwright from $150.00 to $145.00 in ...
Fintel on MSN1d
HC Wainwright & Co. Upgrades Sarepta Therapeutics (SRPT)
Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...
Rezolve AI (NASDAQ:RZLV) Coverage Initiated by Analysts at HC Wainwright
Investment analysts at HC Wainwright began coverage on shares of Rezolve AI (NASDAQ:RZLV – Get Free Report) in a research ...
Inventiva achieves milestone with Phase 3 study enrollment, says H.C. Wainwright
H.C. Wainwright analyst Ed Arce affirms a Buy rating on shares of Inventiva (IVA) after the company announced the completion of patient ...
Mineralys Therapeutics price target raised to $42 from $30 at H.C. Wainwright
H.C. Wainwright analyst Matthew Caufield raised the firm’s price target on Mineralys Therapeutics (MLYS) to $42 from $30 and keeps a Buy rating ...
Fintel on MSN3d
HC Wainwright & Co. Initiates Coverage of Virax Biolabs Group (VRAX) with Buy Recommendation
Fintel reports that on March 31, 2025, HC Wainwright & Co. initiated coverage of Virax Biolabs Group (NasdaqCM:VRAX) with a ...
Aptose Biosciences price target raised to $6 from $2 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Aptose Biosciences (APTO) to $6 from $2 and keeps ...
Yahoo Finance14d
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
A webcast replay will be available on the VYNE website for 90 days following the event. About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing ...
Nasdaq15d
HC Wainwright & Co. Initiates Coverage of RenovoRx (RNXT) with Buy Recommendation
Fintel reports that on March 27, 2025, HC Wainwright & Co. initiated coverage of RenovoRx (NasdaqCM:RNXT) with a Buy recommendation. As of March 19, 2025, the average one-year price target for ...
Nasdaq1y
HC Wainwright & Co. Initiates Coverage of Virax Biolabs Group (VRAX) with Buy Recommendation
Fintel reports that on March 31, 2025, HC Wainwright & Co. initiated coverage of Virax Biolabs Group (NasdaqCM:VRAX) with a Buy recommendation. As of January 19, 2024, the average one-year price ...